Results 161 to 170 of about 912,795 (359)

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study

Hepatology, EarlyView., 2022
A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan, André Megarbane, Aziz Chouchane, Deepak Karthik, Ramzi Temanni, Atilio Reyes Romero, Huiying Hua, Chun Pan, Xixi Chen, Murugan Subramanian, Chadi Saad, Hamdi Mbarek, Cybel Mehawej, Eliane Chouery, Sirin W. Abuaqel, Alexander Dömling, Sami Remadi, Cesar Yaghi, Pu Li, Lotfi Chouchane   +19 more
wiley   +1 more source

Chronic Hepatitis B in Pregnancy [PDF]

Clinical Liver Disease, 2018
Tatyana, Kushner, Monika, Sarkar
openaire   +2 more sources

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Journal of Hepatology, 2017
P. Lampertico, K. Agarwal, T. Berg, M. Buti, H. Janssen, G. Papatheodoridis, F. Zoulim, F. Tacke   +7 more
semanticscholar   +1 more source

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection

, 2013
Background & Aims: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or ...
Simone Susser (48294), Annika Brodzinski, Thomas Berg (186372), Migaud, Pascal, Jacob George (205614), Brodzinski, Annika, Tobias Müller, Susser, Simone, Stephan Böhm (334611), Sarrazin, Christoph, Christoph Sarrazin (48298), Pascal Migaud, Schott, Eckart, Bömmel, Florian van, Heiko Witt, Florian van Bömmel, Janett Fischer, Christoph Sarrazin, Stewart, Graeme, Graeme Stewart, Witt, Heiko, Thomas Berg, Simone Susser, Balazs Fülöp, Fülöp, Balazs, Stephan Böhm, Annika Brodzinski (477753), Balazs Fülöp (477754), Müller, Tobias, Fischer, Janett, Böhm, Stephan, Berg, Thomas, Tobias Müller (163591), Janett Fischer (477751), Eckart Schott (320945), Graeme Stewart (208243), Jacob George, Heiko Witt (161481), Pascal Migaud (477752), George, Jacob, Eckart Schott, Florian van Bömmel (477755)   +41 more
core   +1 more source

Revertant Mosaicism Obscures Long‐Awaited Molecular Confirmation of Diamond‐Blackfan Anemia

American Journal of Medical Genetics Part A, EarlyView.
Nicholas A. Borja, Mustafa Tekin
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz, Seza Ozen, Hacer N. Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet E. Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet O. Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Attacking the public health crisis of hepatocellular carcinoma at its roots

Hepatology, EarlyView., 2022
Abstract As the third most common cause of cancer‐related death worldwide with significant mortality rates in the United States, hepatocellular carcinoma has strong association with cirrhosis and chronic hepatitis B virus (HBV) with a growing at‐risk population from the rise in chronic liver disease from alcohol use and nonalcoholic fatty liver disease.
Hannah M. Lee, Steven D. Lidofsky, Tamar H. Taddei, Lisa J. Townshend‐Bulson   +3 more
wiley   +1 more source

Management of chronic hepatitis B: an update

Swiss Medical Weekly, 2011
Since the publication in 2009 of clinical practice guidelines for the management of hepatitis B virus (HBV) infection by the European Association for the Study of the Liver (EASL), a wealth of new data has emerged regarding the antivirals most commonly used to treat chronic hepatitis B. This review will summarise the most recent knowledge on these
openaire   +5 more sources

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source